Matching articles for "Axiron"
Safety of Testosterone Replacement Therapy
The Medical Letter on Drugs and Therapeutics • March 14, 2016; (Issue 1490)
Three coordinated double-blind, placebo-controlled
clinical trials have evaluated the efficacy of one year of
testosterone replacement therapy in improving sexual
function, physical function, and vitality in...
Three coordinated double-blind, placebo-controlled
clinical trials have evaluated the efficacy of one year of
testosterone replacement therapy in improving sexual
function, physical function, and vitality in a total of
790 men ≥65 years old with moderately low serum
testosterone concentrations and symptoms suggesting
hypoandrogenism. Sexual function improved
modestly, and there appeared to be marginal benefits
in some areas of physical function and vitality as well.
The trials were not designed to evaluate the safety of
testosterone replacement therapy.
Testosterone Nasal Gel (Natesto) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 11, 2015; (Issue 1468)
The FDA has approved an intranasal gel formulation of
testosterone (Natesto – Trimel/Endo) for replacement
therapy in men with hypogonadism. Packaged in a
metered-dose pump, Natesto is the first...
The FDA has approved an intranasal gel formulation of
testosterone (Natesto – Trimel/Endo) for replacement
therapy in men with hypogonadism. Packaged in a
metered-dose pump, Natesto is the first intranasal
testosterone to become available in the US. Like other
testosterone products, it is classified as a schedule
III controlled substance. The FDA recently cautioned
against using testosterone to treat low testosterone
levels solely due to aging because the benefits and
safety of such use have not been established, and there
is a possible increased risk of myocardial infarction (MI)
and stroke.
A Long-Acting Depot Formulation of Testosterone (Aveed)
The Medical Letter on Drugs and Therapeutics • March 31, 2014; (Issue 1439)
The FDA has approved testosterone undecanoate (Aveed –
Endo), an injectable depot formulation, for use in men
with hypogonadism who require testosterone...
The FDA has approved testosterone undecanoate (Aveed –
Endo), an injectable depot formulation, for use in men
with hypogonadism who require testosterone replacement
therapy.
Testosterone Topical Solution (Axiron) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • July 11, 2011; (Issue 1368)
The Medical Letter recently reviewed a topical gel formulation
of testosterone (Fortesta) for treatment of
hypogonadism in men. A topical testosterone replacement
product for application to the axilla,...
The Medical Letter recently reviewed a topical gel formulation
of testosterone (Fortesta) for treatment of
hypogonadism in men. A topical testosterone replacement
product for application to the axilla, Axiron (Lilly)
solution, has now become available for the same indication.
This site of application presumably minimizes
the risk of transferring the drug to a family member or
sexual partner.